MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ma, J. F.
Right arrow Articles by Melera, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ma, J. F.
Right arrow Articles by Melera, P. W.

0026-895X/97/060922-09$3.00/0
Copyright © by The American Society for Pharmacology and Experimental Therapeutics
All rights of reproduction in any form reserved.
MOLECULAR PHARMACOLOGY 51:922-930 (1997).

Mutations in the Sixth Transmembrane Domain of P-Glycoprotein that Alter the Pattern of Cross-resistance Also Alter Sensitivity to Cyclosporin A Reversal

Jian Feng Ma, Geraldine Grant, and Peter W. Melera

Department of Biochemistry and Molecular Biology (J.F.M., G.G., P.W.M.), The Graduate Program in Molecular and Cell Biology (J.F.M., P.W.M.), and the Cancer Center (P.W.M.), University of Maryland School of Medicine, Baltimore, Maryland 21201

The expression of a P-glycoprotein (Pgp1) cDNA encoding two amino acid substitutions in the sixth transmembrane domain of the protein (G338A339 to A338P339) confers a unique cross-resistance profile that displays preferential resistance to actinomycin D and diminished resistance to colchicine and daunorubicin. We report here that this multidrug-resistant phenotype is also insensitive to reversal by cyclosporin A (CsA) but not verapamil (VRP). However, the ability of VRP to increase the accumulation of [3H]vincristine is poor in both wild-type and mutant transfectants. In contrast, the accumulation of [3H]vincristine in wild-type versus mutant transfectants in the presence of CsA is dramatically increased. It is the substitution of the alanine residue at position 339 with proline that is primarily responsible for the lowered sensitivity to CsA and for the altered drug accumulation levels. Both substitutions are required to confer the unique cross-resistance profile of the double mutant, although each independently confers a specific profile of its own. These results indicate that alterations in Pgp1 structure can differentially affect the activity of CsA and VRP to mediate drug accumulation in multidrug-resistant cells and support the conclusion that the sixth transmembrane domain of the Pgp1 transporter plays important roles, in both the specificity of drug efflux and the sensitivity of the transporter to reversal agents.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
G. F. Ecker, E. Csaszar, S. Kopp, B. Plagens, W. Holzer, W. Ernst, and P. Chiba
Identification of Ligand-Binding Regions of P-Glycoprotein by Activated-Pharmacophore Photoaffinity Labeling and Matrix-Assisted Laser Desorption/Ionization-Time-of-Flight Mass Spectrometry
Mol. Pharmacol., March 1, 2002; 61(3): 637 - 648.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. Song and P. W. Melera
Transmembrane Domain (TM) 9 Represents a Novel Site in P-Glycoprotein That Affects Drug Resistance and Cooperates with TM6 to Mediate [125I]Iodoarylazidoprazosin Labeling
Mol. Pharmacol., August 1, 2001; 60(2): 254 - 261.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
D. J. Gruol, J. Bernd, A. E. Phippard, I. Ojima, and R. J. Bernacki
The Use of a Novel Taxane-Based P-Glycoprotein Inhibitor to Identify Mutations That Alter the Interaction of the Protein with Paclitaxel
Mol. Pharmacol., July 1, 2001; 60(1): 104 - 113.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
G. K. Chen, N. J. Lacayo, G. E. Durán, D. Cohen, and B. I. Sikic
Loss of Cyclosporin and Azidopine Binding Are Associated with Altered ATPase Activity by a Mutant P-glycoprotein with Deleted Phe335
Mol. Pharmacol., April 1, 2000; 57(4): 769 - 777.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
T. W. Loo and D. M. Clarke
Identification of Residues in the Drug-binding Domain of Human P-glycoprotein. ANALYSIS OF TRANSMEMBRANE SEGMENT 11 BY CYSTEINE-SCANNING MUTAGENESIS AND INHIBITION BY DIBROMOBIMANE
J. Biol. Chem., December 10, 1999; 274(50): 35388 - 35392.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
T. Shoshani, S. Zhang, S. Dey, I. Pastan, and M. M. Gottesman
Analysis of Random Recombination between Human MDR1 and Mouse Mdr1a cDNA in a pHaMDR-Dihydrofolate Reductase Bicistronic Expression System
Mol. Pharmacol., October 1, 1998; 54(4): 623 - 630.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics